TriSalus Life Sciences, Inc.
corporate_fare Company Profile
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for TLSI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-22, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 8/10, with 10 rated 8 or above. Recent SEC coverage for TLSI spans 4, 10-Q, 8-K, DEF 14A.
Recent high-impact activity:
- FDA Clears TriSalus' TriNav Advance, Expanding PEDD Portfolio for Liver Embolization
- Director Michael Stansky Buys $1.53M in TriSalus Life Sciences Stock
- Q1 2026 Results Show Operational Decline, Non-Cash Profit from Falling Stock, Unremediated Material Weakness
- TriSalus Reports Mixed Q1 Results, Lowers 2026 Revenue Guidance, Secures $46M Equity
- $46M Equity Raise, Revised 2026 Guidance Follow TriSalus' Q1 Revenue Decline
Financial Snapshot
Short Interest & Short Volume
28.81 days to coverFINRA reported short interest of 3,345,269 shares in TLSI as of the September 15, 2026 settlement, a 9.4% decrease from the prior period — about 28.8 days to cover at its recent average daily volume. On October 2, 2026, 80.6% of TLSI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.